- Loblaw’s adjusted earnings per share (EPS) for the second quarter was C$2.40, surpassing both the previous year’s C$2.15 and the estimated C$2.33.
- The company’s food retail comparable sales increased by 3.5%, a significant improvement from last year’s 0.2% growth.
- Drug retail comparable sales saw a rise of 4.1%, compared to the 1.5% growth seen in the previous year.
- Loblaw’s total revenue reached C$14.67 billion, up 5.2% from the previous year, beating the expected C$14.62 billion.
- President and CEO Per Bank attributed strong sales and market share growth to Canadians valuing the company’s commitment to quality, service, and value.
- The company’s stock has received 8 buy ratings, 3 hold ratings, and 2 sell ratings from analysts.
A look at Loblaw Cos Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts are optimistic about the long-term outlook for Loblaw Companies Limited, a prominent retail and wholesale food distributor in Canada. With a solid Smartkarma Smart Score in Momentum and strong ratings in Growth and Resilience, Loblaw Cos is positioned for continued success in the market. The company’s ability to adapt to market trends and maintain a steady growth trajectory bodes well for its future performance.
While Loblaw Cos received average scores in Value and Dividend, its exceptional performance in Momentum reflects a positive sentiment towards the company’s short-term prospects. As a key player in the Canadian retail landscape, Loblaw Cos is expected to leverage its strong operations and strategic positioning to drive future growth and sustain its competitiveness in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
